Epigenomics Regains Rights for Tamoxifen
Treatment Response Test from Roche
Epigenomics has regained full rights to a tamoxifen treatment response test from Roche Diagnostics, the company said this week.
Epigenomics, which is focused on developing tests based on DNA methylation, said that it will now handle the full development of the test itself.
The tissue-based test is designed to predict the probability of disease recurrence in breast cancer patients, and was part of a multi-product collaboration with Roche Diagnostics, Epigenomics said.